N-{3-[9-Ethyl-2-(trans-4-hydroxy-cyclo-hexylamino)-9H-purin-6-yl-amino]-phenyl}-4,4-dimethyl-2-pentynylic acid amide | 289479-91-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N-{3-[9-Ethyl-2-(trans-4-hydroxy-cyclo-hexylamino)-9H-purin-6-yl-amino]-phenyl}-4,4-dimethyl-2-pentynylic acid amide
• CAS: 289479-91-0
• 化学式: C₂₆H₃₃N₇O₂
• 分子量: 475.594
• InChiKey: WNFDAMUJNDGILP-IRJFHVNHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.29
• 重原子数：
  35.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  116.99
• 氢给体数：
  4.0
• 氢受体数：
  8.0

文献信息

• 2-Amino-6-anilino-purines and their use as medicaments
  申请人：——

  公开号：US20020016329A1

  公开（公告）日：2002-02-07

  2-Amino-6-anilino-purine derivatives of the formula I 1 in which the symbols are as defined in claim 1, are described. These compounds inhibit p34 cdc2 /cyclin B cdc13 kinase and protein tyrosine kinase pp60 c-src and can be used for treatment of hyperproliferative diseases, for example tumor diseases, and diseases which respond to inhibition of the activity of protein tyrosine kinase pp60 c-src , in particular osteoporosis.

  公式I中定义的符号如权利要求书1中所定义的那样，描述了1的2-氨基-6-苯胺基嘌呤衍生物。这些化合物抑制p34 cdc2/cyclin B cdc13激酶和蛋白酪氨酸激酶pp60 c-src，并可用于治疗过度增殖性疾病，例如肿瘤疾病，以及对蛋白酪氨酸激酶pp60 c-src活性抑制有反应的疾病，特别是骨质疏松症。
• 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS
  申请人：Novartis AG

  公开号：EP1153024B1

  公开（公告）日：2004-04-28
• JP2002537300A
  申请人：——

  公开号：JP2002537300A

  公开（公告）日：2002-11-05
• US6767906B2
  申请人：——

  公开号：US6767906B2

  公开（公告）日：2004-07-27
• [EN] 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS<br/>[FR] 2-AMINO-6-ANILINO-PURINES ET LEUR UTILISATION COMME MEDICAMENTS
  申请人：NOVARTIS AG

  公开号：WO2000049018A1

  公开（公告）日：2000-08-24

  2-Amino-6-anilino-purine derivatives of formula (I) in which R1 is -S(O)k-NR6R7 or-N(aryl lower alkyl) carbamoyl or -NH-S(O)i-R8 or -NH-C(O)-R9; 9 is 1-5; These compounds inhibit p34cdc2/cyclin Bcdc13 kinase and protein tyrosine kinase pp60c-src and can be used for treatment of hyperproliferative diseases, for example tumour diseases, and diseases which respond to inhibition of the activity of protein tyrosine kinase pp60c-src, in particular osteoporosis.